These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
91 related articles for article (PubMed ID: 2242261)
21. Natural killer cells in children with malignant solid tumors. Effect of recombinant interferon-alpha and interleukin-2 on natural killer cell function against tumor cell lines. Alvarado CS; Findley HW; Chan WC; Hnath RS; Abdel-Mageed A; Pais RC; Kutner MH; Ragab AH Cancer; 1989 Jan; 63(1):83-9. PubMed ID: 2783377 [TBL] [Abstract][Full Text] [Related]
22. Antitumor activities of subsets of human IL-2-activated natural killer cells in solid tissues. Vujanovic NL; Yasumura S; Hirabayashi H; Lin WC; Watkins S; Herberman RB; Whiteside TL J Immunol; 1995 Jan; 154(1):281-9. PubMed ID: 7995947 [TBL] [Abstract][Full Text] [Related]
23. Metastatic renal cancer treated with interleukin-2 and lymphokine-activated killer cells. A phase II clinical trial. Fisher RI; Coltman CA; Doroshow JH; Rayner AA; Hawkins MJ; Mier JW; Wiernik P; McMannis JD; Weiss GR; Margolin KA Ann Intern Med; 1988 Apr; 108(4):518-23. PubMed ID: 3258138 [TBL] [Abstract][Full Text] [Related]
24. Responses of killer cells in head and neck cancer patients. Fujieda S; Saito H; Hoshino T Eur Arch Otorhinolaryngol; 1990; 247(3):176-81. PubMed ID: 2350510 [TBL] [Abstract][Full Text] [Related]
25. A pilot study of intralymphatic interleukin-2. I. Cytotoxic and surface marker changes of peripheral blood lymphocytes. Shau H; Isacescu V; Ibayashi Y; Tokuda Y; Golub SH; Fahey JL; Sarna GP J Biol Response Mod; 1990 Feb; 9(1):71-80. PubMed ID: 2319261 [TBL] [Abstract][Full Text] [Related]
26. Changes in immunological parameters during interleukin 2 and interferon 2 alpha treatment of recurrent renal cell carcinoma and malignant melanoma. Maxwell W; McDevitt J; Reid I; Sharpe I; Feighery C; Tanner WA; Emmons R; Monson JR Eur J Surg Oncol; 1993 Jun; 19(3):265-72. PubMed ID: 8314385 [TBL] [Abstract][Full Text] [Related]
27. Pilot study of interleukin-2 and lymphokine-activated killer cells combined with immunomodulatory doses of chemotherapy and sequenced with interferon alfa-2a in patients with metastatic melanoma and renal cell carcinoma. Sznol M; Clark JW; Smith JW; Steis RG; Urba WJ; Rubinstein LV; VanderMolen LA; Janik J; Sharfman WH; Fenton RG J Natl Cancer Inst; 1992 Jun; 84(12):929-37. PubMed ID: 1629914 [TBL] [Abstract][Full Text] [Related]
28. Defective natural immunity: an early manifestation of human immunodeficiency virus infection. Ullum H; Gøtzsche PC; Victor J; Dickmeiss E; Skinhøj P; Pedersen BK J Exp Med; 1995 Sep; 182(3):789-99. PubMed ID: 7650485 [TBL] [Abstract][Full Text] [Related]